

# Dual action of neurokinin-1 antagonists on Mas-related GPCRs

Ehsan Azimi,<sup>1</sup> Vemuri B. Reddy,<sup>1</sup> Kai-Ting C. Shade,<sup>2</sup> Robert M. Anthony,<sup>2</sup> Sebastien Talbot,<sup>3</sup> Paula Juliana Seadi Pereira,<sup>1,4</sup> and Ethan A. Lerner<sup>1</sup>

<sup>1</sup>Cutaneous Biology Research Center, Department of Dermatology, and <sup>2</sup>Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA. <sup>3</sup>FM Kirby Neurobiology Center, Children's Hospital Boston, Boston, Massachusetts, USA. <sup>4</sup>Programa de Pós-graduação em Biologia Celular e Molecular, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.

The challenge of translating findings from animal models to the clinic is well known. An example of this challenge is the striking effectiveness of neurokinin-1 receptor (NK-1R) antagonists in mouse models of inflammation coupled with their equally striking failure in clinical investigations in humans. Here, we provide an explanation for this dichotomy: Mas-related GPCRs (Mrgprs) mediate some aspects of inflammation that had been considered mediated by NK-1R. In support of this explanation, we show that conventional NK-1R antagonists have off-target activity on the mouse receptor MrgprB2 but not on the homologous human receptor MRGPRX2. An unrelated tripeptide NK-1R antagonist has dual activity on MRGPRX2. This tripeptide both suppresses itch in mice and inhibits degranulation from the LAD-2 human mast cell line elicited by basic secretagogue activation of MRGPRX2. Antagonists of Mrgprs may fill the void left by the failure of NK-1R antagonists.

## Introduction

The neurokinin-1 receptor (NK-1R) and its neuropeptide ligand, substance P (SP), have been implicated in mouse models of human conditions, including emesis (1), asthma (2), and migraine (3). Antagonists to NK-1R were developed and found to be effective in animal models of diseases. This success in animals led to NK-1R antagonists being evaluated in many clinical trials over the past two decades. NK-1R antagonists were found to be effective in the treatment of nausea and vomiting associated with chemotherapy but failed to improve inflammation and nociception (1, 4–7). The discrepancy surrounding the efficacy of NK-1R antagonists in animal models and their failure in clinical trials has not been understood (4, 7).

Mast cells express NK-1R and contribute to inflammation and allergic reactions via IgE-independent and IgE-dependent mechanisms. With respect to the IgE-independent mechanism, a pivotal study revealed that basic secretagogues, which include SP, compound 48/80, cationic peptide antibiotics, and drugs associated with pseudoallergic reactions, activate MRGPRX2 and the mouse ortholog, MrgprB2, to induce mast cell degranulation (8). In contrast, IgE-dependent responses are not mediated through Mas-related GPCRs (Mrgprs) (8).

Here, we suggest that a differential effect of NK-1R antagonists on human versus mouse Mrgprs may solve the mystery of the differential efficacy of NK-1R antagonists in animal models versus clinical trials. We investigated the activity of the structurally related NK-1R antagonists L733060, used widely in mouse studies, and aprepitant, an approved drug, on human MRGPRX2 and mouse MrgprB2. Neither of these antagonists effected the activation of human MRGPRX2 by SP. However, they inhibited the activation of mouse MrgprB2 by SP. We therefore asked if an unrelated NK-1R antagonist might serve a dual function as an antagonist of human MRGPRX2. This question is answered in the affirmative, with the finding that a tripeptide NK-1R antagonist, termed QWF (9), is also an antagonist of both the relevant human and mouse Mrgprs in vitro and in vivo. QWF blocks the binding of SP to mouse and human Mrgprs and inhibits IgE-independent mast cell degranulation and itch induced by basic secretagogues.

## Results

*SP activates human MRGPRX2, mouse MrgprB2, and mouse MrgprA1 in addition to NK-1R.* In rodents, as compared with primates, Mrgprs are widely expanded (10, 11). A single human Mrgpr could thus be

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Submitted:** July 1, 2016


**Accepted:** September 1, 2016

**Published:** October 6, 2016

**Reference information:**

JCI Insight. 2016;1(16):e89362.


doi:10.1172/jci.insight.89362.



**Figure 1. Concentration-effect curves of substance P on NK-1R and Mrgprs.** HeLa cells were transfected with cDNAs encoding NK-1R, mouse MrgprB2, and mouse MrgprA1. A stably transfected HEK293 cell line was used for human MRGPRX2. Intracellular calcium ( $[Ca^{2+}]_i$ ) was determined by ratiometric Fura-2 imaging after addition of substance P (SP). SP is known to activate NK-1R, human MRGPRX2, and mouse MrgprB2, as confirmed here. SP also activates mouse MrgprA1 but not several other mouse Mrgprs or human MRGPRX1, X3, and X4 (Supplemental Figure 1). The  $EC_{50}$ s of SP for NK-1R, MRGPRX2, MrgprA1, and MrgprB2 are 0.5 nM, 100 nM, 5  $\mu$ M, and 50  $\mu$ M, respectively. These differential responses served to guide the concentrations of SP and antagonists used in the remainder of the studies. All data points are triplicates, and studies were performed at least twice.

homologous to several mouse Mrgprs. It has been reported that mouse MrgprB2 is the ortholog of human MRGPRX2. However, ligands that activate both human MRGPRX2 and mouse MrgprB2 are more active on the human MRGPRX2. The  $EC_{50}$  of SP for hMRGPRX2 is approximately 150 nM, while the  $EC_{50}$  of SP for mMrgrprB2 is approximately 50  $\mu$ M (8). MRGPRX2 has been reported to be expressed on mast cells and dorsal root ganglions (DRGs) in humans and primates (12–15), whereas MrgprB2 is expressed exclusively on mouse mast cells. This line of reasoning leads to the suggestion that a distinct Mrgpr on mouse sensory nerves may also serve as an ortholog to human MRGPRX2. Previous studies revealed that MrgprA1 is exclusively expressed at functional levels (16) on mouse DRGs but not mast cells (8, 11, 16). We evaluated the interaction of SP with several mouse Mrgprs and found that SP activates mouse MrgprA1 (Figure 1 and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/jci.insight.89362DS1). The  $EC_{50}$  of SP on MrgprA1 was 10 times better than on MrgprB2 (Figure 1). These results indicate that the mouse receptors MrgprA1 and MrgprB2 are each homologous to human MRGPRX2.

*NK-1R antagonists are also antagonists of mouse MrgprB2.* NK-1R antagonists are effective in mouse models, and SP is an agonist of both NK-1R and the mouse MrgprB2. We therefore asked if established NK-1R antagonists could block the capacity of SP to activate MrgprB2. We found that the NK-1R antagonists L733060 and aprepitant each prevented activation of mouse MrgprB2 by SP (Figure 2). This observation is critical, as it can explain the inconsistencies among clinical trials of NK-1R antagonists in humans and mouse models of inflammatory disease, as described further in the Discussion, and as it shows that mouse MrgprB2 and human MRGPRX2 are important for inflammation. L733060 is effective in mouse models, most likely by antagonizing both NK-1R and, as reported here, MrgprB2. Aprepitant has limited effectiveness in humans because it is an antagonist of NK-1R but not MRGPRX2.




**Figure 2. NK-1R antagonists are selective antagonists of mouse and human Mrgrs.** L733060 (top row) and aprepitant (middle row) inhibit substance P-induced (SP-induced) activation of NK-1R and mouse MrgrB2 but do not inhibit human MRGPRX2 and mouse MrgrA1. QWF (bottom row) inhibits SP-induced activation of human MRGPRX2, mouse MrgrB2, and mouse MrgrA1. HeLa cells were transfected with cDNAs encoding NK-1R, mouse MrgrB2, and mouse MrgrA1. A stably transfected HEK293 cell line was used for human MRGPRX2. Intracellular calcium ( $[Ca^{2+}]_i$ ) was determined by ratiometric Fura-2 imaging after addition of SP and antagonists. The concentration of SP for each receptor is based on the  $EC_{50}$ s (Figure 1). The concentrations of the antagonists are used to balance out the concentration of SP. Each trace is a response from a different cell, and studies in each panel were performed at least twice.

*Identification of QWF as a dual NK-1R and Mrgr antagonist.* We next asked if an unrelated competitive NK-1R antagonist would serve additionally as an antagonist of the human receptor MRGPRX2. We selected the tripeptide NK-1R antagonist Gln-D-Trp(Foranyl)-Phe benzyl ester, abbreviated with the single amino acid letter code as QWF. QWF was effective at preventing SP from activating NK-1R, mouse MrgrB2, mouse MrgrA1, and human MRGPRX2, as measured by calcium imaging of receptor activation (Figure 2). QWF was also effective at preventing the binding of SP to NK-1R, mouse MrgrB2, mouse MrgrA1, and human MRGPRX2 (Figure 3A). The capacity of QWF block the activation of MRGPRX2 was also evaluated (Figure 3B). We also evaluated the interaction of QWF with human MRGPRX1, mouse MrgrA3, PAR2, histamine-1 receptor, and melanocortin-1 receptor in the presence of their ligands. QWF did not affect the activation of these receptors by their ligands (Supplemental Figure 3).

*QWF inhibits activation of human MRGPRX2 by basic secretagogues and by medications associated with pseudoallergic drug reactions.* Basic secretagogues and drugs that are associated with pseudoallergic reactions interact with human MRGPRX2 to induce IgE-independent mast cell degranulation (8). We therefore asked if QWF could inhibit this process. QWF indeed inhibited activation of human MRGPRX2 by compound 48/80; atracurium, a neuromuscular blocking agent; and ciprofloxacin, an antibiotic, as determined by Fura-2 calcium imaging in heterologous cells (Supplemental Figures 3 and 4). These studies with QWF were extended to mouse MrgrB2 with similar results (Supplemental Figures 3 and 4).

*QWF inhibits IgE-independent degranulation from human LAD2 mast cells.* We next asked if QWF would inhibit mast cell degranulation induced by basic secretagogues and drugs associated with pseudoallergic reactions. QWF indeed inhibited degranulation by SP, compound 48/80, atracurium, and ciprofloxacin




**Figure 3. The binding of substance P to Mrgprs is inhibited by QWF.** (A) ELISA was used to quantify the binding of substance P (SP) to nontransfected HEK293 cells and cells expressing human MRGPRX2, mouse MrgprB2, and mouse MrgprA1. SP binding is inhibited by QWF. *P* values for HEK293 SP vs. MRGPRX2 SP, MRGPRX2 SP vs. MRGPRX2 QWF+SP, HEK293 SP vs. MrgprB2 SP, MrgprB2 SP vs. MrgprB2 QWF+SP, HEK293 SP vs. MrgprA1 SP, and MrgprA1 SP vs. MrgprA1 QWF +SP are 0.0024, 0.0002, 0.0018, 0.0037, 0.0042, and 0.0012, respectively. HeLa cells were transfected with cDNAs encoding mouse MrgprB2 and mouse MrgprA1. A stably transfected HEK293 cell line was used for human MRGPRX2. \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\*\**P* ≤ 0.001. (B) Concentration-effect curves with SP versus the indicated concentrations of QWF on a HEK293 cell line stably expressing human MRGPRX2. The results are consistent with QWF being a competitive antagonist of SP on human MRGPRX2. See Supplemental Figure 2 for the interaction of QWF with other GPCRs implicated in itch. The studies in A were performed 3 times and those in B were performed twice. 2-tailed unpaired Student's *t* test was used.

(Figure 4 and Supplemental Figure 5 and 6). These results suggested that human MRGPRX2 antagonists could potentially prevent pseudoallergic drug reactions.

*QWF is an antagonist of compound 48/80–induced Mrgpr activation and scratching in mice.* We next asked if the in vitro findings above could be extended in vivo. We selected scratching behavior in mice, a correlate to itching in humans. We evaluated the capacity of QWF to affect receptor activation in vitro and scratching behavior in vivo by compound 48/80, an established pruritogen. Compound 48/80 is a polymer that induces mast cell degranulation and provokes itch in humans and mice (17, 18). It had been thought that compound 48/80 provokes itch via mast cell degranulation and was thus histamine dependent. It was subsequently determined that compound 48/80, and SP, provoke similar numbers of scratching bouts in WT and mast cell–deficient mice (17). These results revealed that mast cells were not critical for itch provoked by these compounds in mice. It was suggested that mast cells may thus play a modulatory role (17). In addition, compound 48/80 directly interacts with sensory nerves, potentially through Mrgprs (19). Since QWF antagonizes the interaction of compound 48/80 with Mrgprs, we examined the capacity of QWF to block compound 48/80–provoked itch. Compound 48/80 activates human MRGPRX2, mouse MrgprB2 (expressed on mouse mast cells), and mouse MrgprA1 (expressed on mouse DRGs). QWF antagonized the activation of these Mrgprs by compound 48/80 and significantly inhibited scratching provoked by compound 48/80 (Figure 5). Since MrgprA1 is expressed on nerves and is activated by compound 48/80, our results could explain the observations with compound 48/80 and SP in mast cell–deficient mice.

*SP-induced itch is not decreased in NK-1R KO mice.* We next sought to begin to clarify the links among SP, NK-1R, itch, and urticaria, with a consideration of the role of SP and Mrgprs in these conditions. Injection of SP into the skin of humans induces urticarial (20), and patients with chronic urticaria exhibit enhanced wheal reactions to SP as compared with healthy controls (21). These observations are important, as the etiology of up to 50% of patients suffering from chronic urticaria remains unknown, antihistamines are typically not effective, an association with IgE-mediated degranulation can not be established (22), and a recent study of patients with severe chronic urticaria demonstrated upregulated expression of human MRGPRX2 (23). A separate study demonstrated that NK-1R antagonists do not block SP-induced degranulation of human mast cells (24). Several NK-1R antagonists have been tried for treating itch with conflicting results (25, 26), and many of these antagonists have entered clinical trials without, to our knowledge, evaluation in *NK-1R*<sup>-/-</sup> mice (7).



**Figure 4. The effect of QWF on IgE-independent mast cell degranulation.** The level of mast cell degranulation was assessed by the release of  $\beta$ -hexosaminidase in mast cell granules, as quantified by the level of its substrate, *p*-nitrophenyl *N*-acetyl- $\beta$ -D-glucosamide (PNAG), digested in a colorimetric assay. QWF inhibits the degranulation induced by substance P (SP) ( $P < 0.0001$ ), compound 48/80 ( $P = 0.0001$ ), atracurium ( $P = 0.0025$ ), and ciprofloxacin ( $P = 0.0039$ ) in LAD2 mast cells.  $*P \leq 0.05$ ,  $**P \leq 0.01$ ,  $***P \leq 0.001$ ,  $****P \leq 0.0001$ . These studies were performed 3 times using 2-tailed unpaired Student's *t* test.

We compared SP-induced itch between WT and *NK-1R*<sup>-/-</sup> mice. Remarkably, SP-induced itch was not decreased in *NK-1R*<sup>-/-</sup> mice (Figure 6A). As SP activates Mrgprs, and Mrgprs have been implicated in itch, we evaluated the effect of QWF on SP-induced itch (Figure 6, B and C). Since QWF is a dual NK-1R/Mrgpr inhibitor, we coinjected QWF with SP in *NK-1R*<sup>-/-</sup> mice. SP-induced itch was significantly decreased in these mice. To confirm and extend these findings, we evaluated the effect of QWF on SP-induced itch in WT mice. QWF significantly decreased SP-induced itch in WT mice. These data indicate that SP-induced itch may be mediated by Mrgprs rather than NK-1R.

## Discussion


A plethora of studies over the past decade have implicated Mrgprs in nociception and inflammation (27–30). While the expression of most Mrgprs is restricted to sensory dorsal root ganglion neurons, human MRGPRX2 and the mouse ortholog MrgprB2, are expressed on mast cells (8, 31). Human MRGPRX2 and mouse MrgprB2 mediate IgE-independent mast cell degranulation induced by basic secretagogues, including SP, implicating Mrgprs not only in nociception but also in inflammation (8).

Given that human MRGPRX2 and mouse MrgprB2, rather than NK-1R, mediate SP-induced mast cell degranulation (8), it is possible that the antiinflammatory properties observed with NK-1R antagonists in animal models may have been the result of the interaction of these drugs with mouse MrgprB2. Several studies have demonstrated a role for mast cells in inflammatory conditions, including asthma (32) and migraine (33), for which NK-1R antagonists were expected to work. We suggest that these antagonists were not effective in clinical trials because NK-1R does not mediate SP-induced mast cell degranulation and because NK-1R antagonists, as reported here, do not interact with human MRGPRX2. Put another way, a previously unidentified off-target effect of NK-1R antagonists on Mrgprs mediates their effects in mice, and NK-1R itself may not be responsible for the proinflammatory properties of SP on mast cells.

MRGPRX2-specific antagonists have not yet been reported. The NK-1R antagonists evaluated here additionally block mouse MrgprB2. The effects of these agents in animal models thus can not be differentiated in WT mice. The use of these dual antagonists in NK-1R KO mice can help to clarify the contribution of Mrgprs to inflammatory models but does not eliminate a role for NK-1R. The separate contributions of NK-1R and MrgprB2 await the availability of MrgprB2 KO mice or receptor-specific antagonists.

Our findings, that SP-mediated scratching in mice correlates with Mrgpr activation as opposed to NK-1R activation, are the first to our knowledge to indicate a physiologic consequence of Mrgpr activation to an endogenous ligand. It was reported previously that scratching provoked by cathepsin S was mediated by cleavage of MrgprC11 (28). SP activates MrgprB2, MrgprA1, and MRGPRX2 in addition to NK-1R; Mrgprs have otherwise been considered orphan receptors. MRGPRX2 can be activated by a number of peptides, including cortistatin-14, the proadrenomedullin C-terminal peptides PAMP-12 and -20, and LL-37, but physiological consequences have not been identified (12, 13, 34).


The similar number of SP-induced scratching bouts reported in WT and mast cell-deficient mice (17) can now be explained as follows: MrgprB2 is expressed on mast cells and thus absent in mast cell-deficient mice (16). MrgprA1 is expressed at functional levels on nerves and MrgprB2 is not (11, 16). As mouse MrgprA1 is 10-fold more sensitive to SP than mouse MrgprB2, scratching in WT and mast cell-deficient mice is driven by the interaction between SP and mouse MrgprA1. Studies in human subjects reveal that subcutaneous pre-



**Figure 5. QWF is an antagonist of compound 48/80-induced Mrgpr activation and itch provocation.** (A-F) QWF inhibits activation of human MRGPRX2, mouse MrgrB2, and mouse MrgrA1 by compound 48/80. (G) Compound 48/80-induced itch is significantly decreased after coinjection with QWF ( $P = 0.002$ ). Studies in A-F were performed at least twice. The study in panel G was performed twice using 2-tailed unpaired Student's  $t$  test was used.  $*P \leq 0.05$ ,  $***P \leq 0.01$ .

treatment with compound 48/80 inhibits SP-provoked itch (20). This observation has been confirmed in mice (17, 35). Given that mast cells are not the major mediators of SP- or compound 48/80-provoked itch in mice, the simple explanation that pretreatment with compound 48/80 depletes histamine from mast cells is not satisfactory (17, 36). The direct interaction of compound 48/80 and SP with a common receptor on mouse sensory nerves, presumably MrgrA1, and desensitization of this receptor by 48/80 can explain the observation. Compound 48/80 does not activate NK-1R, which was previously thought to mediate SP-provoked itch. We emphasize that mouse MrgrB2 is much more sensitive to compound 48/80 as compared to SP (8), therefore mast cells may play a prominent role in compound 48/80-induced itch in mice as compared with SP.

Several conclusions can be drawn from the data reported here. First, L733060 and aprepitant turn out to be dual antagonists of NK-1R and mouse MrgrB2 but not human MRGPRX2. Second, the differential effect of NK-1R antagonists on mouse versus human Mrgrs can explain the inconsistencies with respect to their efficacy in mouse models as compared with a range of human conditions. Third, while MrgrB2 may play an important role in mast cell degranulation and inflammation in mice, MrgrA1 may be important for sensing itch. Fourth, several NK-1R antagonists are in clinical trials for treatment of inflammatory skin disease, uremic itch, and cholestatic itch or may be advanced to later stage trials. An evaluation of their interaction with human MRGPRX2 may be relevant in predicting their outcome, as the data presented



**Figure 6. Scratching from substance P is maintained in *NK-1R*<sup>-/-</sup> mice and is blocked by QWF.** (A) Itch induced by substance P (SP) (500  $\mu$ M) is not decreased in *NK-1R*<sup>-/-</sup> mice compared with WT mice. (B) SP-induced itch is significantly decreased ( $P = 0.0040$ ) in *NK-1R*<sup>-/-</sup> mice after coinjection with QWF (500  $\mu$ M). (C) SP-induced itch is significantly decreased ( $P = 0.0134$ ) in WT mice after coinjection with QWF (500  $\mu$ M). These studies were performed twice using 2-tailed unpaired Student's *t* test. \* $P \leq 0.05$ , \*\* $P \leq 0.01$ .

here suggest that antagonism of human MRGPRX2 may be relevant to the treatment of SP-associated itch. While it is tempting to suggest that QWF may have a therapeutic role as a result of its antagonism of NK-1R and MRGPRX2, the tripeptide is rapidly metabolized in plasma (37), limiting its efficacy. The implications of the use of human MRGPRX2 antagonists may extend to the treatment of itch and, thus, beyond urticaria and pseudoallergic drug reactions. There are limitations to this study, including that the mouse cheek model of acute itch is not known to resemble a disease condition in humans. In addition, evaluation of the specific roles of NK-1R, MrgprB2, and MrgprA1 in itch or inflammation would benefit from the identification of MrgprA1- or MrgprB2-specific antagonists and the availability of MrgprA1 or mMrgprB2 KO mice. In conclusion, antagonists of MRGPRX2 may have a therapeutic benefit in conditions in which NK-1R antagonists have shown promising results in animal models but failed in humans.

## Methods

**Peptides and chemicals.** SP and SLIGRL were obtained from GenScript and dissolved in PBS. Chloroquine was obtained from Sigma-Aldrich. The NK-1R antagonists, L733060 and QWF (Boc-Gln-D-Trp(Formyl)-Phe benzyl ester trifluoroacetate), were obtained from Sigma-Aldrich, while aprepitant was purchased from Selleckchem. Aprepitant and QWF were dissolved in DMSO at 10 mM and diluted into PBS at 1 mM or lower concentrations.

**Cell culture.** HEK293 and HeLa cells were obtained from ATCC.

**Animals.** C57BL/6 mice were obtained from JAX. *NK-1R*<sup>-/-</sup> mice on a C57BL/6 background were provided by Norma Gerard, Children's Hospital Boston.

**cDNA clones.** Human MRGPRX2 was isolated by PCR from human genomic DNA using the forward and reverse primers, CTCGAGAGCATGGATCCAACCACC and AAGCTTCTCTACACCAGACT-GCTTCTCG, and cloned into pcDNA3.1(-). The mouse MrgprB2 coding sequences were amplified from mouse genomic DNA using the primer pair, CTCGAGAACATGAGTGGAGATTTCTAATCAAG and AAGCTTTCAGCTGCAGCTCTGAACAGTTTCCAG, and cloned into pcDNA3.1(-). Human *NK-1R* cDNA was obtained from Life Technologies, PCR amplified with Xho I-Hind III ends, and cloned into pcDNA3.1(-). All other Mrgprs were cloned by PCR from genomic DNAs and inserted into pcDNA3.1(-).

**Calcium imaging of transfected HeLa cells.** 10  $\mu$ g of expression vector (human MRGPRX2, mouse MrgprB2, or NK-1R) and 10  $\mu$ l of Lipofectamine 2000 transfection reagent were diluted into 0.5 ml of DMEM and separately left at room temperature for 5 minutes. They were then mixed and incubated at room temperature for 20 minutes prior to being added to HeLa cells. HeLa cells were grown to confluence and trypsinized, and  $1 \times 10^6$  cells were pelleted in a 15-ml tube by centrifugation at 250 *g* for 5 minutes. The DMEM-Lipofectamine 2000-DNA mixture (1 ml) was then added to the cell pellet, suspended, and incubated at room temperature for 5 minutes. Two ml of complete DMEM with 10% FBS without antibiotics was added to the tube, mixed by inverting the tube, plated into a 96-well glass bottom plate at 50,000 cells/well, and placed in a 37°C CO<sub>2</sub> incubator for 3 hours. HeLa cells transfected with salmon sperm DNA were plated as a control. The medium was changed after 3 hours and left in the incubator. Twenty-four hours after transfection, the medium in the wells was removed and 100  $\mu$ l of complete DMEM containing 2  $\mu$ M of Fura-2 was added to each well and left at room temperature in the dark for 1 hour. Following loading

with Fura-2, the medium was removed, washed with PBS, and replaced with 90  $\mu$ l of HEPES-buffered saline (20 mM HEPES, 115 mM NaCl, 5.4 mM KCl, 2 mM CaCl<sub>2</sub>, 0.8 mM MgCl<sub>2</sub>, 13.8 mM glucose, pH 7.4). Calcium imaging was performed immediately after loading cells with Fura-2 using a Zeiss Axiovert 200M microscope platform equipped with a flipping filter wheel for ratiometric imaging. Axiovision software, version 4.6, was used for calcium image analysis of the cells excited at 340 nm and 380 nm. Agonists were added at 15 seconds after the start of the excitation procedure, as indicated in Figure 2, 5, and all the Supplemental Figures. Antagonists were added 5 minutes before agonists. Images were taken every 5 seconds, including at 0 time, during a 90-second period, or longer if required. The software later analyzed all images taken during each excitation period. Ratiometric changes were measured in 10–20 cells in each individual experiment. An average of the fluorescence of the cells in each image was calculated, represented as F340/380 in the figures, and plotted against time in seconds. Colored curves in the figures represent responses of representative individual cells.

**Behavioral studies.** The mouse cheek model was used to evaluate scratching behavior (38). Mice were habituated for 30 minutes/day for 3 days prior to the study and for 15 minutes on the day of the study. 10  $\mu$ l of each compound was delivered by a 31-gauge needle to the cheek. Mice were not shaved prior to injections to minimize irritation. All experiments were performed at consistent times during the day (9:00 am to 2:00 pm) and under the same conditions and in groups of 7 mice (4 male, 3 female), the number of mice demonstrated via power calculation to generate significance in behavioral studies. Mice were 2–3 months old and 20–30 g. Mice were videotaped in a soundproof environment to minimize distraction. Recordings were scored for the number of scratching bouts that occurred over 1-minute intervals during 25-minute observation periods, and the investigator was not aware of the group allocation during scoring the study and behavioral analysis. A scratching bout was initiated by lifting of the hind paw to the area of injection and ended by returning of the hind paw to the floor or to the mouth. Compound 48/80 (500  $\mu$ M), SP (500  $\mu$ M), and QWF (500  $\mu$ M) were injected compounds. The concentrations of SP and compound 48/80 were standard for behavioral studies.

**Human LAD2 mast cell culture, degranulation assay, and calcium imaging.** The human LAD2 mast cell line (from D. Metcalfe, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA) was cultured in StemPro-34 SFM medium (Life Technologies) supplemented with 2 mM glutamine, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, and 100 ng/ml recombinant human stem cell factor (Pepro-Tech). The cells were maintained at  $0.25 \times 10^5$  to  $5 \times 10^5$  cells/ml at 37°C and 5% CO<sub>2</sub> and hemidepleted each week. Degranulation was measured as described previously (39). In brief, LAD2 cells were washed before incubation with various concentrations of QWF (1  $\mu$ M, 10  $\mu$ M, 100  $\mu$ M) for 10 minutes before activation by SP (1  $\mu$ M). 100  $\mu$ M QWF was effective at decreasing SP-induced mast cell degranulation, and this concentration was used for studies involving basic secretagogues (1.5  $\mu$ M compound 48/80, 100  $\mu$ M atracurium, and 100  $\mu$ M ciprofloxacin). The level of mast cell degranulation was assessed by the release of  $\beta$ -hexosaminidase in mast cell granules, as quantified by the level of its substrate, *p*-nitrophenyl *N*-acetyl- $\beta$ -D-glucosamide, digested in a colorimetric assay. For calcium studies, methods were identical to those using HeLa cells, except that LAD2 cells were incubated for 24 hours on imaging plates coated with poly-D-lysine to improve the attachment of the cells.

**SP-binding assay by ELISA.** HEK293 MRGPRX2 Cells ( $0.5 \times 10^6$ ) were transferred to 2 tubes in a volume of 500  $\mu$ l PBS. One tube was treated with SP to a final concentration of 1  $\mu$ M for 1 hour at room temperature, and the other tube was first incubated with QWF (100  $\mu$ M) for 10 minutes followed by SP (1  $\mu$ M) for 1 hour. Similar procedure was carried with HEK293 cells transfected with pcDNA3.1(-)mMrgprB2. Control HEK293 cells ( $0.5 \times 10^6$ ) were also treated with SP (1  $\mu$ M) in a similar manner. Cells were pelleted and washed twice with PBS in a volume of 500  $\mu$ l. Supernatants were discarded. Cell pellets were suspended in 300  $\mu$ l of PBS and lysed by two freeze-thaw cycles using liquid nitrogen. The lysates were spun and supernatants were assayed in triplicate using an R&D Systems SP competitive enzyme immunoassay (catalog KGE007). The readings from SP-untreated HEK293 cells as controls were subtracted from the final values.

**Statistics.** For statistical comparison, 2-tailed unpaired Student's *t* test was used to determine significance. Differences were considered to be statistically significant at  $P < 0.05$ . Group data are presented as mean with SEM. Data analysis was performed using Prism 6. All in vitro studies were performed at least 3 times.

**Study approval.** The present studies in mice were reviewed and approved by the Institutional Animal Care and Use Committee at Massachusetts General Hospital, Boston, Massachusetts, USA.



## Author contributions

EA, VBR, and EAL conceived the overall design of the study. EA performed behavioral studies. VBR performed in vitro studies and helped analyze them with EA and EAL. KTCS and RMA performed mast cell studies in conjunction with EA and EAL. ST and PJSP helped with in vitro studies and the structure of the manuscript. All authors contributed to the writing and review of the manuscript.

## Acknowledgments

We thank Tuanlian Luo for technical assistance. Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AR057744 and R21AR067399 to EAL and 5U19AI110495 and 1DP2AR068272 to RMA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. EA is the recipient of a grant from the National Eczema Association.

Address correspondence to: Ethan A Lerner, Department of Dermatology, Massachusetts General Hospital, Cutaneous Biology Research Ctr, 3rd Flr, 149 13th Street, Charlestown, Massachusetts 02129, USA. Phone: 617.726.4439; E-mail: elerner@magh.harvard.edu.

- Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. *N Engl J Med*. 2016;374(14):1356–1367.
- Ramalho R, Soares R, Couto N, Moreira A. Tachykinin receptors antagonism for asthma: a systematic review. *BMC Pulm Med*. 2011;11:41.
- May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine. *Expert Opin Investig Drugs*. 2001;10(4):673–678.
- Rost K, Fleischer F, Nieber K. [Neurokinin 1 receptor antagonists—between hope and disappointment]. *Med Monatsschr Pharm*. 2006;29(6):200–205.
- Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. *Expert Opin Investig Drugs*. 2009;18(12):1843–1864.
- Herbert MK, Holzer P. [Why are substance P(NK1)-receptor antagonists ineffective in pain treatment?]. *Anaesthesist*. 2002;51(4):308–319.
- Hill R. NK1 (substance P) receptor antagonists—why are they not analgesic in humans? *Trends Pharmacol Sci*. 2000;21(7):244–246.
- McNeil BD, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature*. 2015;519(7542):237–241.
- Hagiwara D, Miyake H, Morimoto H, Murai M, Fujii T, Matsuo M. Studies on neurokinin antagonists. 1. The design of novel tripeptides possessing the glutaminyl-D-tryptophylphenylalanine sequence as substance P antagonists. *J Med Chem*. 1992;35(11):2015–2025.
- Solinski HJ, Gudermann T, Breit A. Pharmacology and signaling of MAS-related G protein-coupled receptors. *Pharmacol Rev*. 2014;66(3):570–597.
- Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. *Cell*. 2001;106(5):619–632.
- Kamohara M, et al. Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides. *Biochem Biophys Res Commun*. 2005;330(4):1146–1152.
- Robas N, Mead E, Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. *J Biol Chem*. 2003;278(45):44400–44404.
- Zhang L, et al. Cloning and expression of MRG receptors in macaque, mouse, and human. *Brain Res Mol Brain Res*. 2005;133(2):187–197.
- Tatemoto K, et al. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. *Biochem Biophys Res Commun*. 2006;349(4):1322–1328.
- Goswami SC, et al. Molecular signatures of mouse TRPV1-lineage neurons revealed by RNA-Seq transcriptome analysis. *J Pain*. 2014;15(12):1338–1359.
- Andoh T, Nagasawa T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. *J Pharmacol Exp Ther*. 1998;286(3):1140–1145.
- Wahlgren CF, Hägermark O, Bergström R. Patients' perception of itch induced by histamine, compound 48/80 and wool fibres in atopic dermatitis. *Acta Derm Venereol*. 1991;71(6):488–494.
- Schemann M, et al. The mast cell degranulator compound 48/80 directly activates neurons. *PLoS One*. 2012;7(12):e52104.
- Hägermark O, Hökfelt T, Pernow B. Flare and itch induced by substance P in human skin. *J Invest Dermatol*. 1978;71(4):233–235.
- Boricci-Mazi R, Kouridakis S, Kontou-Fili K. Cutaneous responses to substance P and calcitonin gene-related peptide in chronic urticaria: the effect of cetirizine and dimethindene. *Allergy*. 1999;54(1):46–56.
- Vonakis BM, Saini SS. New concepts in chronic urticaria. *Curr Opin Immunol*. 2008;20(6):709–716.
- Fujisawa D, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. *J Allergy Clin Immunol*. 2014;134(3):622–633.e9.
- Peachell PT, Columbo M, Kagey-Sobotka A, Lichtenstein LM, Marone G. Adenosine potentiates mediator release from human

- lung mast cells. *Am Rev Respir Dis*. 1988;138(5):1143–1151.
25. Wallengren J. Topical aprepitant in clinical and experimental pruritus. *Arch Dermatol*. 2012;148(8):957–959.
26. Wallengren J, Edvinsson L. Topical non-peptide antagonists of sensory neurotransmitters substance P and CGRP do not modify patch test and prick test reactions: a vehicle-controlled, double-blind pilot study. *Arch Dermatol Res*. 2014;306(5):505–509.
27. Liu Q, et al. Mechanisms of itch evoked by  $\beta$ -alanine. *J Neurosci*. 2012;32(42):14532–14537.
28. Reddy VB, Sun S, Azimi E, Elmariah SB, Dong X, Lerner EA. Redefining the concept of protease-activated receptors: cathepsin S evokes itch via activation of Mrgprs. *Nat Commun*. 2015;6:7864.
29. Liu Q, et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. *Cell*. 2009;139(7):1353–1365.
30. Liu Q, et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. *Sci Signal*. 2011;4(181):ra45.
31. Bader M, Alenina N, Andrade-Navarro MA, Santos RA. MAS and its related G protein-coupled receptors, Mrgprs. *Pharmacol Rev*. 2014;66(4):1080–1105.
32. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. *J Allergy Clin Immunol*. 2006;117(6):1277–1284.
33. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. *Brain Res Brain Res Rev*. 2005;49(1):65–76.
34. Subramanian H, Gupta K, Guo Q, Price R, Ali H. Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: resistance to receptor phosphorylation, desensitization, and internalization. *J Biol Chem*. 2011;286(52):44739–44749.
35. Kuraishi Y, Nagasawa T, Hayashi K, Satoh M. Scratching behavior induced by pruritogenic but not algisogenic agents in mice. *Eur J Pharmacol*. 1995;275(3):229–233.
36. Inagaki N, et al. Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. *Eur J Pharmacol*. 2002;448(2-3):175–183.
37. Hagiwara D, Miyake H, Morimoto H, Murai M, Fujii T, Matsuo M. Studies on neurokinin antagonists. 2. Design and structure-activity relationships of novel tripeptide substance P antagonists, N alpha-[N alpha-(N alpha-acetyl-L-threonyl)-N1-formyl-D-tryptophyl]-N-methyl-N-(phenylmethyl)-L-phenylalaninamide and its related compounds. *J Med Chem*. 1992;35(17):3184–3191.
38. Shimada SG, LaMotte RH. Behavioral differentiation between itch and pain in mouse. *Pain*. 2008;139(3):681–687.
39. Kuehn HS, Radinger M, Gilfillan AM. Measuring mast cell mediator release. *Curr Protoc Immunol*. 2010;Chapter 7:Unit7.38.